From 10/01/2017- To 12/31/2017
Proposal Title, ID#, Sponsor, Dates, Direct Cost, Indirect Cost, Total Cost
Duan, Bin, MSC derived myelinating schwann cell for PN regeneration, 21387, NE DHHS – LB606, 10/01/17-06/30/18, $101,500 , $0 , $101,500
Casey, Carol A, Altered Lipid Droplet Trafficking Role in Alcoholic Fatty Liver Disease, 19689, DHHS/NIH/NIAAA, 05/01/17-04/30/18, $57,596 , $0 , $57,596
Casey, Carol A, Nebraska Center for Integrated Biomolecular Communication (CIBC), 20437, University of Nebraska – Lincoln, 08/01/17-06/30/18, $3,456 , $1,745 , $5,201
Singh, Shailender, Pancreatic Cystic Reference Set, 20827, University of Pittsburgh, 04/01/17-03/31/18, $7,389 , $3,731 , $11,120
Singh, Shailender, Pancreatic Cystic Reference Set, 20827, University of Pittsburgh, 04/01/17-03/31/18, ($3,615), ($1,825), ($5,440)
Ashraf, Muhammad S, Quasi Experimental Before and After Study to Evaluate the Effect of Training Consultant Pharmacists for Promoting Optimal Antibiotic Use in Long-term Care Facilities, 20975, Merck Sharp & Dohme Corp., 10/01/17-09/30/18, $79,532 , $19,898 , $99,430
Florescu, Diana Florentina, A Prospective, Randomized, Double-blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam Compared with Meropenem in Adult Patients with Ventilated Nosocomial Pneumonia, 18185, Cubist Pharmaceuticals, Inc, -, $0 , ($7,836), ($7,836)
Florescu, Diana Florentina, A Prospective, Randomized, Double-blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam Compared with Meropenem in Adult Patients with Ventilated Nosocomial Pneumonia, 18185, Cubist Pharmaceuticals, Inc, -, ($40,336), ($2,459), ($42,795)
Florescu, Diana Florentina, Phase II Multi-Center,Prospective, Randomized, Double-Blind Study of Nitazoxanide in Acute and Chronic Norovirus in Hematopoietic Stem Cell and Solid Organ Transplant Recipients, 19040, Northwestern University-Chicago, 04/04/17-10/03/18, $89,035 , $33,638 , $122,673
Kalil, Andre C, (ARLG) Antibacterial Resistance Leadership Group: Achaogen Lung PK, 20336, Duke University, 12/01/16-11/30/17, $22,768 , $11,498 , $34,266
Swindells, Susan, AIDS Clinical Trials Group (ACTG): Protocol Chair Support, 20097, Brigham & Women's Hospital, 12/01/16-11/30/17, $12,500 , $6,313 , $18,813
Swindells, Susan, Title III:Categorical Grant Program to Provide Outpatient Early Intervention Services with Respect to HIV Disease (Ryan White Part C Outpatient EIS Program), 6247, DHHS/HRSA, 01/01/17-12/31/17, $360,403 , $0 , $360,403
Swindells, Susan, Ryan White Part B Supplemental, 21469, NE DHHS, 09/30/17-09/29/18, $2,500,000 , $0 , $2,500,000
Swindells, Susan, A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label study evaluating the efficacy, safety, and tolerability of Long acting Cabotegravir plus long acting Rilpivirine administered every 8 weeks or every 4 weeks in HIV-1 infect, 21408, GlaxoSmithKline, 01/01/18-12/31/20, $0 , $91,184 , $91,184
Swindells, Susan, A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label study evaluating the efficacy, safety, and tolerability of Long acting Cabotegravir plus long acting Rilpivirine administered every 8 weeks or every 4 weeks in HIV-1 infect, 21408, GlaxoSmithKline, 01/01/18-12/31/20, $470,610 , $30,395 , $501,005
Vanschooneveld, Trevor Craig, A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of Rebiotix RBX2660 (microbiota suspension) for the Prevention of Recurrent Clostridium difficile Infection, 21118, Rebiotix Inc., 12/01/17-05/31/19, $0 , $7,119 , $7,119
Vanschooneveld, Trevor Craig, A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of Rebiotix RBX2660 (microbiota suspension) for the Prevention of Recurrent Clostridium difficile Infection, 21118, Rebiotix Inc., 12/01/17-05/31/19, $39,508 , $2,373 , $41,881
Bhatt, Vijaya R, A Randomized, Phase II, Multi-Center, Open Label Study Comparing Sirolimus to Prednisone in Patients with Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease, 19917, National Marrow Donor Program, 10/01/16-10/20/20, $16,456 , $4,608 , $21,064
Bhatt, Vijaya R, A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies, 21119, Incyte Corporation, 12/07/17-11/26/19, $0 , $74,461 , $74,461
Bhatt, Vijaya R, A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies, 21119, Incyte Corporation, 12/07/17-11/26/19, $384,853 , $24,821 , $409,674
Bhatt, Vijaya R, A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs. host disease after allogenic stem cell transplantation, 21286, Incyte Corporation, 12/08/17-11/28/19, $0 , $119,162 , $119,162
Bhatt, Vijaya R, A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs. host disease after allogenic stem cell transplantation, 21286, Incyte Corporation, 12/08/17-11/28/19, $612,086 , $39,720 , $651,806
Lunning, Matthew A, AN EXPLORATORY PHASE 1/2 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF JCAR017 COMBINATIONS IN SUBJECTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES (PLATFORM), 21315, Celgene Corporation, 11/25/17-11/24/19, $0 , $81,526 , $81,526
Lunning, Matthew A, AN EXPLORATORY PHASE 1/2 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF JCAR017 COMBINATIONS IN SUBJECTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES (PLATFORM), 21315, Celgene Corporation, 11/25/17-11/24/19, $421,084 , $27,176 , $448,260
Schwarz, James Kendal, A Phase 1B, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 and ANTI-PD-L1 (Atezolizumab) in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer or Metastatic Non-Small Cell Lung Cancer, 21326, Nektar Therapeutics, 11/01/17-10/31/19, $0 , $123,850 , $123,850
Schwarz, James Kendal, A Phase 1B, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 and ANTI-PD-L1 (Atezolizumab) in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer or Metastatic Non-Small Cell Lung Cancer, 21326, Nektar Therapeutics, 11/01/17-10/31/19, $638,129 , $41,284 , $679,413
Tandra, Pavankumar, A Randomized, Open Label, Phase III Trial to Evaulate the Efficacy & Safety of Palbociclib+Anti-HER2 Therapy+Endocrine Therapy vs Anti-HER2 Therapy+Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Br, 21075, Alliance Foundation Trials, LLC, 12/11/17-12/10/18, $142,444 , $36,255 , $178,699
Vose, Julie M, A Phase 1/2 Proof-of-Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects with Relapsed/Refractory B-cell Malignancies, 21320, Acerta Pharma BV, 11/01/17-10/31/19, $0 , $62,141 , $62,141
Vose, Julie M, A Phase 1/2 Proof-of-Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects with Relapsed/Refractory B-cell Malignancies, 21320, Acerta Pharma BV, 11/01/17-10/31/19, $325,672 , $20,714 , $346,386
Bailey, Kristina Lynn, Mucociliary clearance in aging, 19544, DHHS/NIH/NIA, 05/01/17-04/30/18, $20,501 , $10,352 , $30,853
Dickinson, John David, CF Lung Transplant Transition LLC-Referring CF Program, 21535, Dartmouth College, 10/01/17-10/16/18, $31,000 , $2,480 , $33,480
Grant, Kathleen M, Intensive Referral to Al-Anon: Benefits to Concerned Others and Their Drinkers, 20806, Palo Alto Institute for Reseach and Education, Inc., 07/01/17-06/30/18, $96,883 , $25,189 , $122,072